Malady Kyle 4

What Happened

• Kyle Malady, EVP and Group CEO — VZ Business, received a grant of 123.227 phantom stock units on February 12, 2026. The filing reports a per‑unit value of $14.11, for an economic value of approximately $1,739. This transaction is an award/derivative (reported as an acquisition of phantom stock), not an open‑market purchase or sale.

Key Details

• Transaction date: 2026-02-12; Filing date: 2026-02-17 (check the original Form 4 for any timeliness code).
• Transaction type/code: Award/Grant of derivative securities (phantom stock) — reported as "A".
• Quantity & valuation: 123.227 phantom stock units @ $14.11 each ≈ $1,739 total.
• Shares owned after transaction: Not specified in the provided summary — see the full Form 4 for post‑transaction holdings.
• Footnotes: F1 — each phantom share is cash‑settled and payable per the deferred compensation plan; F2 — the amount includes phantom stock acquired via dividend reinvestment.
• No indication here of a sale, exercise for stock issuance, or tax‑withholding share transfer.

Context

• Phantom stock units give economic exposure to Verizon common stock and are settled in cash per the deferred compensation plan; they do not represent issued common shares or immediate ownership voting rights.
• The reported value is modest (~$1.7k), so this award is likely a routine deferred compensation/retention item rather than a market‑moving insider purchase. Always consult the complete Form 4 for full ownership details and any additional notes.